{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:46:36Z","timestamp":1776743196440,"version":"3.51.2"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,4,1]],"date-time":"2027-04-01T00:00:00Z","timestamp":1806537600000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["5K12CA076930"],"award-info":[{"award-number":["5K12CA076930"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clml.2025.11.006","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T17:06:59Z","timestamp":1763658419000},"page":"e483-e491.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of Personal Credit Data With Financial Hardship and Treatment Outcomes in Patients With Multiple Myeloma"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2700-2650","authenticated-orcid":false,"given":"Christopher T.","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-5682","authenticated-orcid":false,"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6478-0769","authenticated-orcid":false,"given":"Catherine","family":"Fedorenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veena","family":"Shankaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.clml.2025.11.006_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(15)00151-9","article-title":"Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study","volume":"2","author":"Huntington","year":"2015","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.clml.2025.11.006_bib0002","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/NCC.0b013e3182693522","article-title":"Personal financial effects of multiple myeloma and its treatment","volume":"36","author":"Goodwin","year":"2013","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.clml.2025.11.006_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2024.02.013","article-title":"Financial toxicity, time toxicity, and quality of life in multiple myeloma","volume":"24","author":"Banerjee","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.clml.2025.11.006_bib0004","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.clml.2023.01.008","article-title":"The dynamics of financial toxicity in multiple myeloma","volume":"23","author":"Fiala","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.clml.2025.11.006_bib0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-022-00671-z","article-title":"Financial toxicity in hematological malignancies: a systematic review","volume":"12","author":"Ouchveridze","year":"2022","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2025.11.006_bib0006","first-page":"153","article-title":"The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment","volume":"68","author":"Carrera","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.clml.2025.11.006_bib0007","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw205","article-title":"Financial hardships experienced by cancer survivors: a systematic review","volume":"109","author":"Altice","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.clml.2025.11.006_bib0008","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.6004\/jnccn.2019.7305","article-title":"Financial burdens of cancer treatment: a systematic review of risk factors and outcomes","volume":"17","author":"Smith","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.clml.2025.11.006_bib0009","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/cam4.1246","article-title":"Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis","volume":"6","author":"Ailawadhi","year":"2017","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.clml.2025.11.006_bib0010","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-022-00681-x","article-title":"Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study","volume":"12","author":"Buradagunta","year":"2022","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.clml.2025.11.006_bib0011","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.bbmt.2014.12.024","article-title":"Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma","volume":"21","author":"Costa","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.clml.2025.11.006_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2023.08.008","article-title":"Disparities in multiple myeloma treatment patterns in the United States: a systematic review","volume":"23","author":"Gasoyan","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"25","key":"10.1016\/j.clml.2025.11.006_bib0013","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.11.006_bib0014","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.02834","article-title":"Financial toxicity monitoring in a randomized controlled trial of patient-reported outcomes during cancer treatment (Alliance AFT-39)","volume":"41","author":"Blinder","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.11.006_bib0015","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.6004\/jnccn.2020.7581","article-title":"A pilot study of a comprehensive financial navigation program in patients with cancer and caregivers","volume":"18","author":"Watabayashi","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2025.11.006_bib0016","doi-asserted-by":"crossref","DOI":"10.1200\/OP.22.00056","article-title":"Financial toxicity intervention improves outcomes in patients with hematologic malignancy","volume":"18","author":"Knight","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"10.1016\/j.clml.2025.11.006_bib0017","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jacr.2022.10.011","article-title":"Defining the role of the modern oncology provider in mitigating financial toxicity","volume":"20","author":"Su","year":"2023","journal-title":"J Am Coll Radiol"},{"issue":"18","key":"10.1016\/j.clml.2025.11.006_bib0018","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1002\/cncr.35367","article-title":"Interventions to mitigate cancer-related medical financial hardship: a systematic review and meta-analysis","volume":"130","author":"Rashidi","year":"2024","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.clml.2025.11.006_bib0019","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1002\/cncr.28814","article-title":"The development of a financial toxicity patient-reported outcome in cancer: the COST measure","volume":"120","author":"de Souza","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clml.2025.11.006_bib0020","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/cncr.30369","article-title":"Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial toxicity (COST)","volume":"123","author":"de Souza","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clml.2025.11.006_bib0021","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/OP-24-00598","article-title":"Development and validation of a simplified financial toxicity screening tool for use in clinical practice","volume":"21","author":"Thom","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"7","key":"10.1016\/j.clml.2025.11.006_bib0022","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/annonc\/mdz140","article-title":"Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications","volume":"30","author":"Witte","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.11.006_bib0023","article-title":"Navigating financial toxicity in patients with cancer: a multidisciplinary management approach","volume":"72","author":"Smith","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.clml.2025.11.006_bib0024","doi-asserted-by":"crossref","first-page":"igae016","DOI":"10.1093\/geroni\/igae016","article-title":"Does consumer credit precede or follow health among older adults? An investigation in the advanced cognitive training for independent and vital elderly (ACTIVE) trial","volume":"8","author":"Dean","year":"2024","journal-title":"Innov Aging"},{"issue":"10","key":"10.1016\/j.clml.2025.11.006_bib0025","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/jamainternmed.2022.3687","article-title":"Association of chronic disease with patient financial outcomes among commercially insured adults","volume":"182","author":"Becker","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"8","key":"10.1016\/j.clml.2025.11.006_bib0026","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.21.01636","article-title":"Risk of adverse financial events in patients with cancer: evidence from a novel linkage between cancer registry and credit records","volume":"40","author":"Shankaran","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.11.006_bib0027","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/jamainternmed.2020.6432","article-title":"Financial presentation of Alzheimer disease and related dementias","volume":"181","author":"Nicholas","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.clml.2025.11.006_bib0028","doi-asserted-by":"crossref","DOI":"10.1200\/JOP.19.00309","article-title":"Timeliness of initial therapy in multiple myeloma: trends and factors affecting patient care","volume":"16","author":"Kumar","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"7","key":"10.1016\/j.clml.2025.11.006_bib0029","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1182\/blood-2015-05-647636","article-title":"Guidelines for determination of the number of prior lines of therapy in multiple myeloma","volume":"126","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.11.006_bib0030","unstructured":"Determining lines of therapy (LOT) in oncology in claims databases. Optum. Accessed Jan 8, 2022. https:\/\/cdn-aem.optum.com\/content\/dam\/optum3\/optum\/en\/resources\/white-papers\/wf520768_guidelines-for-determining-lines-of-therapy.pdf"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.11.006_bib0031","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/1475-6773.13092","article-title":"Neighborhood disadvantage and chronic disease management","volume":"54","author":"Durfey","year":"2019","journal-title":"Health Serv Res"},{"issue":"9","key":"10.1016\/j.clml.2025.11.006_bib0032","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.30526","article-title":"Racial disparities in treatment use for multiple myeloma","volume":"123","author":"Fiala","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.11.006_bib0033","article-title":"Association of insurance disparities and survival in adults with multiple myeloma: a non-concurrent cohort study","volume":"104","author":"Makhani","year":"2021","journal-title":"Leuk Re"},{"issue":"5","key":"10.1016\/j.clml.2025.11.006_bib0034","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1159\/000514671","article-title":"Survival disparities in multiple myeloma by health insurance status among US non-elderly adults: a SEER-based comparative analysis","volume":"144","author":"Huang","year":"2021","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2025.11.006_bib0035","unstructured":"Economic Well-Being of U.S. Households in 2021: dealing with unexpected expenses. Board of Governors of the Federal Reserve Accessed Jul 25, 2022. https:\/\/www.federalreserve.gov\/publications\/2022-economic-well-being-of-us-households-in-2021-dealing-with-unexpected-expenses.htm"},{"issue":"12","key":"10.1016\/j.clml.2025.11.006_bib0036","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1377\/hlthaff.2016.0842","article-title":"The financial burdens of high-deductible plans","volume":"35","author":"Abdus","year":"2016","journal-title":"Health Aff (Millwood)"},{"issue":"7","key":"10.1016\/j.clml.2025.11.006_bib0037","doi-asserted-by":"crossref","first-page":"459.e1","DOI":"10.1016\/j.jtct.2025.04.015","article-title":"Out-of-pocket expenditures and financial hardship among patients with myelodysplastic syndrome undergoing allogeneic transplant or hypomethylating agent \/supportive care (BMT CTN 1102)","volume":"31","author":"Su","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.clml.2025.11.006_bib0038","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/OP.24.00415","article-title":"Financial toxicity screening preferences in patients with breast cancer","volume":"21","author":"Gharzai","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"4","key":"10.1016\/j.clml.2025.11.006_bib0039","doi-asserted-by":"crossref","DOI":"10.1002\/cfp2.1135","article-title":"Predicting mortality from credit reports","volume":"4","author":"De Giorgi","year":"2021","journal-title":"Financial Planning Rev"},{"issue":"6","key":"10.1016\/j.clml.2025.11.006_bib0040","first-page":"565","article-title":"Patient navigation across the cancer care continuum: an overview of systematic reviews and emerging literature","volume":"73","author":"Chan","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2025.11.006_bib0041","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2025.4371","article-title":"Can we use credit data to assess cancer financial hardship?","author":"Su","year":"2025","journal-title":"JAMA Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:17:16Z","timestamp":1776741436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2152265025042922"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.11.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Personal Credit Data With Financial Hardship and Treatment Outcomes in Patients With Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}